Fujimoto Seiyaku

Fujimoto Pharmaceutical is a specialized Japanese pharmaceutical and medical device company headquartered in Osaka. The firm is best known for its pioneering work in the orphan drug space, particularly for the re-introduction and safety management of thalidomide (Thaled) in Japan for multiple myeloma and erythema nodosum leprosum. In addition to its pharmaceutical business, Fujimoto develops and manufactures a range of medical devices, including cardiovascular catheters and interventional products. The company operates with a vertically integrated model that includes research, development, and GMP-compliant manufacturing facilities. Fujimoto often acts as a strategic partner for international firms looking to navigate the Japanese regulatory landscape for niche or orphan indications.